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Abstract
Background: Adhesive small intestine occlusion [ASIO] is an important cause of hospital admission placing a
substantial burden on healthcare systems worldwide. Often times, ASIO is associated with significant morbidity
and mortality.
Icodextrin 4% solution [Adept, Shire Pharmaceuticals, UK] is a high-molecular-weight a-1,4 glucose polymer that
is approved in Europe for use as an intra-operative lavage and a post-operative instillate to reduce the occurrence
of post-surgery intra-abdominal adhesions.
There are no randomized trials on the use of this solution to prevent adhesions after ASIO operation in current
medical literature.
The current clinical study evaluates the safety and effectiveness of Icodextrin 4% for decreasing the incidence,
extent, and severity of adhesions in patients after abdominal surgery for ASIO.
Design: The study project is a prospective, randomized controlled investigation performed in the Department
of Transplant, General and Emergency Surgery of St. Orsola-Malpighi University Hospital [Bologna, Italy]. The
study is designed and conducted in compliance with the principles of Good Clinical Practice regulations.
The study compares the results of Icodextrin 4% against a control group who does not receive anti-adhesion
treatment. This randomized study uses a double-blind procedure to evaluate efficacy end points. In other words,
designated third party individuals who are unaware of the treatment assigned to the patients to assess adhesion
formation.
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Introduction
Adhesive small intestine occlusion [ASIO] is an important
cause of hospital admission placing a substantial burden
on healthcare systems worldwide. Often times, ASIO is
associated with significant morbidity and mortality. Post-
operative adhesions account for > 40 percent of all cases
of intestinal obstruction, with 60 to 70 percent of those
involving the small bowel [1]. Of patients who require
multiple abdominal operation, 30 to 44 percent have
adhesion-related intestinal obstruction [2]. For small-
bowel obstruction, the incidence rises to 65 to 75 percent
[3]. Mortality rates range from 3 percent for simple intes-
tinal obstructions to 30 percent when the bowel becomes
necrotic or perforated [3].
The overall recurrence rate for patients who underwent
one operation for ASIO is 18% after 10 years and 29% at
30 years. For patients admitted several times for ASIO, the
relative risk of recurring ASIO increased in relation to the
number of prior ASIO episodes. The cumulative recur-
rence rate reached 81% for patients with 4 or more ASIO
admissions [4]. In the US, adhesiolysis is responsible for
> 300,000 hospitalizations annually, accounting for
nearly 850,000 days of inpatient care and $1.3 billion in
hospitalization and surgical expenditures [5].
An increasing number of adhesion-reduction agents, in
the form of site-specific and broad-coverage barriers and
solutions, are becoming available to surgical teams to
complement optimal surgical techniques. Icodextrin 4%
solution [Adept, Shire Pharmaceuticals, UK] is a high-
molecular-weight a-1,4 glucose polymer that is approved
in Europe for use as an intra-operative lavage and a post-
operative instillate to reduce the occurrence of post-sur-
gery intra-abdominal adhesions [6]. The icodextrin col-
loid is absorbed slowly, resulting in the retention of the
fluid within the peritoneal cavity for more than 4 days.
The solution reduces adhesions by a process of hydroflo-
tation, keeping the peritoneal organs and tissues apart
during the critical post-surgery period when the patient is
at greatest risk of adhesion formation [7]. 1 Icodextrin has
an extensive safety profile and has been used as a 7.5%
solution in continuous ambulatory peritoneal dialysis
[CAPD] for > 50,000 patient-years. In addition, preclinical
and preliminary clinical studies have demonstrated the
safety and efficacy of Icodextrin 4% solution in the reduc-
tion of adhesion formation following abdominopelvic
surgery [8].
There are no randomized trials on the use of this solution
to prevent adhesions after ASIO operation currently
present in the medical literature.
The current clinical study evaluates the safety and effec-
tiveness of Icodextrin 4% for decreasing the incidence,
extent, and severity of adhesions in patients after abdom-
inal surgery for ASIO.
Methods
The project is a prospective, randomized controlled inves-
tigation performed in the Department of Transplant, Gen-
eral and Emergency Surgery of St. Orsola-Malpighi
University Hospital [Bologna, Italy]. The study is designed
and conducted in compliance with the principles of Good
Clinical Practice regulations.
A computer-generated schedule creates the randomized
assignments for the subject and control groups and the
results are sealed in numbered envelopes. Participation in
the study is requested after diagnosing small bowel
obstruction caused by adhesions and determining if the
patient fulfills the inclusion criteria [subjects who elect to
undergo the surgical laparotomy]. Accordingly to the pro-
tocol, the patient signs a document indicating his or her
consent and the responsible surgeon discloses the enve-
lope.
If after opening the sealed envelope containing the assign-
ments, the patient declines to enter the trial, the case is
excluded from the study [all dropped-out patients are
reported].
The responsible surgeon will record the patient's name
[and number].
Each group has a sample size of 88 patients [176 patients
for the whole study].
All randomized patients [Intention to Treat population]
are included in the analysis.
Sample size has been calculated to reach a confidence
level of 95% with a power of 80%.
A sample size of 88 patients each group [65 analyzable] is
calculated supposing that the ASIO patients [first, second,
third or fourth operation for ASIO] have a mean risk of
50% to develop a further episode of ASIO and this risk can
be decreased by 25% [from 50% to 25%] with the use of
Icodextrin 4%
Inclusion criteria are:
Adult patients [> 18 years]
Submitted to laparotomic surgical procedures for ASIO
Clinical and radiological evidence of adhesive small intes-
tine obstructionTrials 2008, 9:74 http://www.trialsjournal.com/content/9/1/74
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Positive history of radiotherapy
Patients with an intra-operative findings of different
pathology will be excluded from the study
Preoperative data include patient demographics, comor-
bid conditions [genitourinary, cardiac, pulmonary, gas-
trointestinal, renal, or rheumatologic] and a detailed
history of previous occlusions and surgical procedures.
Decompression with a nasogastric tube is carried out in
order to calculate the average nasogastric tube output of
each patient [total amount of drainage/duration]. For
patients administered Gastrografin before surgery, only
the output before the procedure is considered. Intrave-
nous fluid therapy is performed.
Plain abdomen X-rays are done and maximal small intes-
tine diameter is calculated. Duration of symptoms before
admission and number of previous operations are also
evaluated.
Subjects with ASIO who elect to undergo the surgical
laparotomy are enrolled in the study; written informed
consent is obtained from each individual and then they
are randomized into the study groups. Laparotomic surgi-
cal procedure is carried out and existing abdominal cavity
adhesions are documented. Subjects are submitted to
adhesiolysis with bowel resection if necessary with or
without anastomosis. The first group receive traditional
treatment [control group] whereas the second group is
treated with Icodextrin 4% before abdomen closure. The
use of irrigants during surgery is not allowed. Peritoneal
contamination is evaluated with cultures.
Per protocol the abdominal fascia is closed with a running
PDS suture and the skin is closed with sutures or skin sta-
ples.
Only one abdominal drainage in allowed in case of bowel
resection and it has to be removed 7 days after the opera-
tion.
In case of bowel leakage, the patient will no longer be
included in the study results.
For all patients, perioperative parameters are recorded,
including blood loss, total length of the midline incision,
method of anastomosis, method and timing of incision
openings and closures, corticosteroid use. Operative
wounds are classified as clean, clean contaminated, and
contaminated as described by Schwartz [9].
Morbility, mortality and postoperative stay are registered.
A flow chart showing the protocol is illustrated in figure 1.
The patients are followed-up for 5 years.
In case of reoperation for ASIO the procedure is carried
out by a third party blinded to the patient's previous anti-
adhesive treatment: this surgeon evaluates incidence,
location, severity, and extent of adhesions. The incidence
of adhesions is assigned a severity score of 0 [no adhe-
sions], 1 [filmy thickness, avascular], 2 [moderate thick-
ness, limited vascularity], or 3 [dense thickness,
vascularized].
Adverse events [AEs] are collected for the duration of the
study, beginning at the time of randomization.
AEs are identified and described by the primary investiga-
tors.
In the control group, patients will be treated as in our
daily surgical practice.
In the informed consent form, patients receive all the
information about the study protocol, confidential data
management and they fill up a questionnaire before sign-
ing or refuse.
There are not inconveniences caused to the patients. No
incentives are planned for the patients regarding the oper-
ation or the follow-up.
There are not any additional risks for the treatment and
control group: both groups have the standard surgical
treatment and follow-up: icodextrin group is an antiad-
herences fluid with no adverse effects.
All the medical information obtained from the patients
are kept confidential among the research scientists con-
ducting the study.
The patients are free to withdraw from the study, when-
ever they want and without any obligation.Trials 2008, 9:74 http://www.trialsjournal.com/content/9/1/74
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The study is approved by the ethical Committee of the
S'Orsola-Malpighi Hospital, Bologna, Italy
The primary endpoints of our study are:
To evaluate the therapeutic role of Icodextrin 4% to
reduce ASIO incidence
To reduce adherences rate [in case of reoperation for
ASIO]
The onset of any other complications are recorded intra-
operatively, postoperatively, at discharge, at 7-days, 1-
month, 6-months, every year up to 5 years follow-up.
The primary outcomes are assessed every year [interim
analysis] up to 5 years after the last enrolled patient.
The data generated by this study are analysed in two ways.
The continuous numerical data are subjected to analysis
of variance [ANOVA], this method being applicable to the
discrimination of two continuous populations. Discrete
data are analysed by the chi-squared test or Fisher exact
test, as appropriate. Statistically significant differences
between study treatments are based on p < 0.05.
The study takes approximately 2 years for the inclusion
period. According to the number of ASIO menaged
monthly by each surgeon in our Department, the duration
of the inclusion period can be approximately 2 years to
reach the number of about 176 enrolled patients.
ASIO is a common disease. Any improvement in this field
will benefit many patients reducing the re-operative rate.
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